Press Releases

Month Year

Investor Alerts

Jan 14, 2014

Karyopharm Therapeutics Announces Data Presentations at American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium

NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Jan 8, 2014

Karyopharm Therapeutics Announces Award of Grant From National Multiple Sclerosis Society to Further Develop Selective Inhibitors of Nuclear Export (SINE) Compounds

NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
Dec 20, 2013

Karyopharm Therapeutics Added to Russell 3000(R) and Russell 2000(R) Indexes

NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Dec 11, 2013

Karyopharm Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering

NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Dec 8, 2013

Karyopharm Therapeutics Presents Promising Data for Selinexor, an Oral, First-in-Class Selective Inhibitors of Nuclear Export (SINE) Compound, in Hematologic Malignancies at 2013 ASH Annual Meeting

NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...

Show per page

Click here to print this page.
Click here to send us an email.
Click here to subscribe to RSS Feed.

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa